An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

This study has been completed.
Sponsor:
Collaborator:
H. Lundbeck A/S
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00734071
First received: August 11, 2008
Last updated: October 25, 2013
Last verified: October 2013
Results First Received: October 25, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Generalized Anxiety Disorder
Interventions: Drug: Vortioxetine
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants took part in the study at 33 investigative sites in the United States from 25 June 2008 to 06 March 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants with a diagnosis of generalized anxiety disorder were enrolled equally in one of two treatment groups, once a day placebo or 5 mg vortioxetine.

Reporting Groups
  Description
Placebo Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
Vortioxetine 5 mg Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.

Participant Flow:   Overall Study
    Placebo     Vortioxetine 5 mg  
STARTED     152     152  
Treated     151     148  
COMPLETED     114     125  
NOT COMPLETED     38     27  
Adverse Event                 4                 3  
Lack of Efficacy                 3                 1  
Noncompliance                 2                 2  
Protocol Deviations                 3                 4  
Voluntary Withdrawal                 9                 7  
Lost to Follow-up                 16                 8  
Other                 1                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
Vortioxetine 5 mg Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
Total Total of all reporting groups

Baseline Measures
    Placebo     Vortioxetine 5 mg     Total  
Number of Participants  
[units: participants]
  152     152     304  
Age  
[units: years]
Mean ± Standard Deviation
  41.4  ± 12.81     41.0  ± 14.05     41.2  ± 13.42  
Age, Customized  
[units: participants]
     
≤55 years     128     129     257  
>55 years     24     23     47  
Gender  
[units: participants]
     
Female     97     103     200  
Male     55     49     104  
Race/Ethnicity, Customized  
[units: participants]
     
Caucasian (White, including Hispanic)     131     123     254  
Black     17     24     41  
Asian     2     3     5  
American Indian or Alaska Native     0     2     2  
Native Hawaiian/ Other Pacific Islander     2     0     2  
Race/Ethnicity, Customized  
[units: participants]
     
Hispanic/Latino     24     26     50  
Non-Hispanic/Non-Latino     128     126     254  
Region of Enrollment  
[units: participants]
     
United States     152     152     304  
Weight  
[units: kg]
Mean ± Standard Deviation
  83.68  ± 20.916     80.10  ± 20.296     81.89  ± 20.652  
Height  
[units: cm]
Mean ± Standard Deviation
  167.73  ± 8.765     167.72  ± 9.158     167.73  ± 8.949  
Body Mass Index (BMI)  
[units: kg/m^2]
Mean ± Standard Deviation
  29.66  ± 6.861     28.42  ± 6.680     29.04  ± 6.789  
Smoking Classification  
[units: participants]
     
Never Smoked     78     76     154  
Current Smoker     38     43     81  
Ex-smoker     36     33     69  
Alcohol Consumption  
[units: participants]
     
Never     48     39     87  
Once monthly or less often     57     55     112  
Once a week     17     28     45  
2 to 6 times per week     27     27     54  
Daily     3     3     6  
Hamilton Anxiety Scale Total Score [1]
[units: scores on a scale]
Mean ± Standard Deviation
  24.6  ± 3.60     24.7  ± 3.79     24.7  ± 3.69  
Clinical Global Impression - Severity scale score [2]
[units: scores on a scale]
Mean ± Standard Deviation
  4.3  ± 0.49     4.3  ± 0.53     4.3  ± 0.51  
Hospital Anxiety and Depression – Anxiety subscale [3]
[units: scores on a scale]
Mean ± Standard Deviation
  13.5  ± 3.14     13.8  ± 3.39     13.7  ± 3.26  
Hospital Anxiety and Depression – Depression subscale [4]
[units: scores on a scale]
Mean ± Standard Deviation
  8.5  ± 3.79     8.1  ± 3.91     8.3  ± 3.85  
Montgomery Åsberg Depression Rating Scale (MADRS) total score [5]
[units: scores on a scale]
Mean ± Standard Deviation
  11.83  ± 3.007     12.09  ± 2.902     11.96  ± 2.953  
[1] Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (absent) to 56 (maximum severity).
[2] The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. The number of participants with available data were 151 and 152 in each treatment arm respectively.
[3] Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). The number of participants with available data were 149 and 151 in each treatment arm respectively.
[4] Hospital Anxiety and Depression (HAD) Depression sub-scale consists of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). The depression subscale focuses on the state of lost interest and diminished pleasure response. Scores are summed and range from 0 to 21 (maximal severity). The number of participants with available data were 149 and 151 in each treatment arm respectively.
[5] The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression).



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8   [ Time Frame: Baseline to Week 8 ]

2.  Secondary:   Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8   [ Time Frame: Baseline to Week 8 ]

3.  Secondary:   Clinical Global Impression Scale-Global Improvement at Week 8   [ Time Frame: Baseline to Week 8 ]

4.  Secondary:   Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8   [ Time Frame: Baseline to Week 8 ]

5.  Secondary:   Percentage of Responders in HAM-A Total Score at Week 8   [ Time Frame: Baseline and Week 8 ]

6.  Secondary:   Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25   [ Time Frame: Baseline to Week 8 ]

7.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8   [ Time Frame: Baseline to Week 8 ]

8.  Secondary:   Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed   [ Time Frame: Baseline to Weeks 1, 2, 4 and 6. ]

9.  Secondary:   Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed   [ Time Frame: Baseline to Weeks 1 and 4 ]

10.  Secondary:   Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed   [ Time Frame: Baseline to Weeks 1, 2, 4 and 6 ]

11.  Secondary:   Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed   [ Time Frame: Baseline to Weeks 1, 2 and 4 ]

12.  Secondary:   Percentage of Responders in HAM-A Total Score at Other Weeks Assessed   [ Time Frame: Baseline and Weeks 1, 2, 4 and 6 ]

13.  Secondary:   Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25   [ Time Frame: Baseline to Weeks 1, 2, 4 and 6 ]

14.  Secondary:   Percentage of Participants in HAM-A Remission at Each Week Assessed   [ Time Frame: Weeks 1, 2, 4, 6 and 8 ]

15.  Secondary:   Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed   [ Time Frame: Baseline to Weeks 1, 2, 4, 6 and 8 ]

16.  Secondary:   Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed   [ Time Frame: Baseline to Weeks 1, 4 and 8 ]

17.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed   [ Time Frame: Baseline to Weeks 2 and 4 ]

18.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed   [ Time Frame: Baseline to Weeks 2, 4 and 8 ]

19.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed   [ Time Frame: Baseline to Weeks 2, 4 and 8 ]

20.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed   [ Time Frame: Baseline to Weeks 2, 4 and 8 ]

21.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed   [ Time Frame: Baseline to Weeks 2, 4 and 8 ]

22.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed   [ Time Frame: Baseline to Weeks 2, 4 and 8 ]

23.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed   [ Time Frame: Baseline to Weeks 2, 4 and 8 ]

24.  Secondary:   Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed   [ Time Frame: Baseline to Weeks 2, 4 and 8 ]

25.  Secondary:   Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire   [ Time Frame: Baseline and Week 8 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Director, Clinical Science
Organization: Takeda
phone: 800-778-2860
e-mail: clinicaltrialregistry@tpna.com


Publications of Results:

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00734071     History of Changes
Other Study ID Numbers: LuAA21004_310, U1111-1114-4876
Study First Received: August 11, 2008
Results First Received: October 25, 2013
Last Updated: October 25, 2013
Health Authority: United States: Food and Drug Administration